The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 353-374

  Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Breast cancer; Docetaxel; Lung cancer; Microtubules; Ovarian cancer; Paclitaxel; Pharmacology; Taxol; Taxotere; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; BLADDER CANCER; CANCER; CANCER PALLIATIVE THERAPY; ESOPHAGUS CANCER; HEAD AND NECK CANCER; LUNG CANCER; MICROTUBULE; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; MICROTUBULES; NEOPLASMS; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0031040149     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.353     Document Type: Review

References (117)

1. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. 1992. Taxol: the prototypic taxane, an important new class of antitumor agents. Sem. Oncol 19:646-62
2. Bissery M-C, Nohynek G, Sanderlink G-J, Lavelle F. 1995. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: Preclinical experience. Anti-Cancer Drugs 6:339-55
3. Rao S, Krauss NE, Heerding JM, et al. 1994. 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of β-tubulin. J. Biol. Chem. 269:3132-34
4. Manfredi JJ, Horwitz SB. 1984. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25:83-125
5. Diaz JF, Andreu JM. 1993. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemistry 32:2747-55
6. Ringel I, Horwitz SB. 1991. Studies with RP56976 (Taxotere): a semisynthetic analogue of taxol. J. Natl. Can. Inst. 83:288-91
7. Jordon MA, Wendell K, Gardiner S, et al. 1996. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:816-25
8. Haldar S, Chintapalli J, Croce CM. 1996. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1253-55
9. Schiff PB, Gubits R, Kashimawo S, Geard CR. 1995. Paclitaxel with ionizing radiation. In Paclitaxel in Cancer Treatment, ed. WG McGuire, EK Rowinsky, pp. 81-90. New York: Dekker
10. Cabral F, Barlow SB. 1991. Resistance to antimitotic agents as genetic probes of microtubule structure and function. Pharm. Ther. 52:159-71
11. Horwitz SB, Cohen D, Rao S, et al. 1993. Taxol: mechanisms of action and resistance. Monogr. Natl. Cancer Inst. 15:63-67
12. Webster L, Linenmyer M, Millward M, et al. 1993. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Can. Inst. 85:1685-90
13. Millward MJ, Webster D, Rischin D, et al. 1996. Plasma concentrations of polysorbate 80 (Tween 80) in patients following docetaxel (Taxotere) or etoposide. Proc. 9th NCI-EORTC Symp. New Drugs Cancer Ther., p. 95 (Abstr.)
14. Seidman AD. 1995. The emerging role of paclitaxel in breast cancer therapy. Clin. Cancer. Res. 1:247-50
15. Colarusso PJ, Ranganathan S, Benetatos CA, et al. 1996. Altered tubulin isotype expression in a non-MDR1 mediated paclitaxel-resistaiit human prostate carcinoma cell line. Proc. Am. Assoc. Can. Res. 37:439 (Abstr.)
16. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. 1988. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48:4093-100
17. Dumontet C, Duran GE, Steger KA, et al. 1996. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 56:1091-97
18. Rowinsky EK. 1995. Pharmacology and metabolism. In Paclitaxel in Cancer Treatment, ed. WG McGuire, EK Rowinsky, pp. 91-120. New York: Dekker
19. Rowinsky EK, Gilbert M, McGuire WP, et al. 1991. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9:1692-703
20. Rowinsky EK, Citardi M, Noe DA, Donehower RC. 1993. Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol. 119:737-43
21. Rowinsky EK, Donehower RC. 1995. Drug therapy: paclitaxel (Taxol). N. Engl. J. Med. 332:1004-14
22. Gianni L, Munzone E, Capri G, et al. 1995. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 13:2688-99
23. Kennedy MJ, Zahurak ML, Donehower RC, et al. 1995. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously-treated metastatic breast cancer. J. Clin. Oncol. 14:783-91
24. Kearns CM, Gianni L, Egorin MJ. 1995. Paclitaxel pharmacokinetics and pharmacodynamics. Sem. Oncol. 22(Suppl. 6):16-23
25. Knick VC, Eberwein DJ, Miller CG. 1995. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J. Natl. Can. Inst. 87:1072-77
26. Bissery MC, Vrignaud P, Bayssas M, Lavelle F. 1995. Preclinical in vivo activity of docetaxel-containing combinations. Proc. Am. Soc. Clin. Oncol. 14:489 (Abstr.)
27. van Oosterom AT, Schrijvers D. 1995. Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II: Clinical experience. Anti-Cancer Drugs 6:356-58
28. Bruno R, Dorr MB, Montay G, et al. 1994. Design and implementation of population pharmacokjnetic studies during the development of docetaxel (RP56976), a new anticancer drug. Clin. Pharmacol. Ther. 55: 161 (Abstr.)
29. Marre F, Sanderink G-J, de Sousa G, et al. 1996. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 56:1296-302
30. Eisenhauer E, ten Bokkel Huinink W, Swenerton KD, et al. 1994. European-Canadian randomized trial of taxol in relapsed ovarian cancer: high vs low dose and long vs short infusion. J. Clin. Oncol. 12:2654-66
31. Wilson WH, Berg S, Bryant G, et al. 1994. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96 hour infusion. J. Clin. Oncol 12:1621-29
32. Hainsworth JD, Thompson DS, Greco FA. 1995. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J. Clin. Oncol. 13:1609-14
33. Cortex JE, Pazdur R. 1995. Docetaxel. J Clin. Oncol. 13:2643-55
34. Oulid-Aissa D, Bruno R, Lebecq A, et al. 1996. Taxotere safety in patients with impaired liver function. Proc. Am. Soc. Clin. Oncol. 15:476 (Abstr.)
35. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. 1993. Clinical toxicities encountered with taxol. Sem. Oncol. 20(Suppl. 3):1-15
36. Weiss R, Donehower RC, Wiernik PH, et al. 1990. Hypersenstivity reactions from taxol. J. Clin. Oncol. 8:1263-68
37. Huizing MT, Keung ACF, Rosing H, et al. 1993. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol. 11:2127-35
38. Gianni L, Kearns C, Gianni A, et al. 1995. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J. Clin. Oncol. 13:180-90
39. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. 1993. The neurotoxicty of taxol. Monogr. Natl. Cancer Inst. 15:107-15
40. Chaudhry V, Rowinsky EK, Sartorius SE, et al. 1994. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. 35:490-97
41. Peretz T, Sulkes A, Chollet P, et al. 1995. A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur. J. Cancer 31A(Suppl. 5):S75 (Abstr.)
42. McGuire WP, Rowinsky EK, Rosenshein NB, et al. 1989. Taxol: a unique antineo-plastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111:273-79
43. Capri G, Munzone E. Tarenzi E. et al. 1994. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J. Natl. Can. Inst. 86:1101
44. Rowinsky EK, McGuire WP, Guarnieri T, et al. 1991.Cardiac disturbances during the administration of taxol. J. Clin. Oncol. 9: 1704-12
45. Arbuck SG, Strauss H, Rowinsky EK, et al. 1993. Areassessment of the cardiac toxicity associated with taxol. Monogr. Natl. Cancer Inst. 15:117-32
46. Burtness B, Harrold L, Beaulieu N, et al. 1996. Use of paclitaxel in patients with cardiomyopathy is safe. Proc. Am. Soc. Clin. Oncol. 15:147 (Abstr.)
47. Rowinsky EK, Burke PJ, Karp JE, et al. 1989. Phase I and pharmacodynamic study of taxol in refractory adult acute leukemia. Cancer Res. 49:4640-47
48. Rowinsky EK, Donehower RC. 1996. Antimicrotubule agents. In Cancer Chemotherapy, ed. B Chabner, J Collins, pp. 263-96. Philadelphia: Lippincott-Raven
49. Einzig AI, Wiernik P, Sasloff J, et al. 1992. Phase II study and long-term follow up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10:1748-53
50. Thigpen T, Blessing J, Ball H, et al. 1994. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group study. J. Clin. Oncol. 12:1748-53
51. Kohn EC, Sarosy G, Bicher A, et al. 1994. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer Inst. 86: 18-24
52. Sarosy G, Kohn E, Stone DA, et al. 1992. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. 10: 1165-70
53. Trimble EL, Adams JD, Vena D, et al. 1993. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Treatment Referral Center 9103. J. Clin. Oncol. 11: 2405-10
54. McGuire WP, Hoskins WJ, Brady MF, et al. 1996. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1-6
55. Omura GA, Brady MF, Delmore JE, et al. 1995. A randomized trial of paclitaxel at 2 dose levels and filgastrim (G-CSF) in platinum pretreated epithelial ovarian cancer: a Gynecologic Oncology Group, SWOG, NCCTG, and ECOG study. Proc: Am. Soc. Clin. Oncol. 15:280 (Abstr.)
56. Rowinsky EK, Mackey MK, Goodman SN. 1995. Meta analysis of paclitaxel dose-response and dose-intensity in recurrent or refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. 15:284 (Abstr.)
57. Kavanagh J, Kudelka A, Gonzales de Leon C, et al. 1994. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. J. Clin. Oncol. 2:837-42
58. Piccart JH, Gore M, ten Bokkel Huinink W, et al. 1995. Docetaxel: an active new drug for the treatment of advanced ovarian cancer. J. Natl. Cancer Inst. 87:686-81
59. Aapro M, Pujade-Lauraine E, Lhomme C, et al. 1994. EORTC Clinical Screening Group: phase II study of Taxotere in ovarian cancer. Ann. Oncol. 5(Suppl. 5):202 (Abstr.)
60. Francis P, Schneider J, Hann L, et al. 1994. Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J. Clin. Oncol. 12:2301-8
61. Holmes FA, Walters RS, Theriault RL, et al. 1991. Phase II trial of taxol, an active drug in metastatic breast cancer. J. Natl. Cancer Inst. 83:1797-805
62. Reichman B, Seidman A, Crown J, et al. 1993. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin. Oncol. 11:1943-51
63. Gianni L, Munzone E, Capri G, et al. 1995. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrent after prior therapy with anthracyclines. J. Natl. Cancer Inst. 87:1169-75
64. Seidman AD, Tiersten A, Hudis C. 1995. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. 13:2575-81
65. Trudeau ME, Eisenhauer EA, Higgins BP, et al. 1996. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J. Clin. Oncol. 14:422-28
66. Hudis CA, Seidman AD, Crown JPA, et al. 1996. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14: 58-65
67. Chevallier B, Fumoleau P, Kerbrat P, et al. 1995. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 13:314-22
68. Fumoleau P, Chevallier B, Dieras V, et al. 1994. Evaluation of two doses of docetaxel (Taxotere) as first-line therapy in advanced breast cancer. Report of the EORTC Clinical Screening Group (EORTC-CSG). Proc. 2nd Eur Congr. Senology, Vienna, Austria (Abstr.)
69. Seidman AD, Reichman BS, Crown JPA, et al. 1995. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol. 13:1152-59
70. Seidman A, Crown J, Reichman B, et al. 1993. Lack of cross-resistance of taxol with anthracycline in the treatment of metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 12:63 (Abstr.)
71. Ravdin P, Burris HA, Cook G, et al. 1995. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin. Oncol. 13: 2879-85
72. Valero V, Holmes FA, Walters RS, et al. 1995. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J. Clin. Oncol. 13:2886-94
73. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. 1994. A phase II trial with docetaxel (Taxotere) in second-line treatment with chemotherapy for advanced breast cancer. Ann. Oncol. 5:527-32
74. Taguchi T, Adachi I, Enomoto K, et al. 1994. Docetaxel (RP56976) in advanced or recurrent breast cancer: early and late phase II clinical studies in Japan. Proc. Am. Soc. Clin. Oncol. 13:331 (Abstr.)
75. Bourgeois H, Gruia G, Dieras V, et al. 1996. Docetaxel in combination with doxorubicin as 1st line CT of metastatic breast cancer: a phase I dose finding study. Proc. Am. Soc. Clin. Oncol. 15:148 (Abstr.)
76. Gelmon K, Nabholtz JM, Bontenbal M, et al. 1994. Randomized trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Ann. Oncol. 5(Suppl. 5):198
77. Murphy WK, Fossella FV, Winn RJ, et al. 1993. Phase II study of taxol in patients with untreated non-small cell lung cancer. J. Natl. Cancer Inst. 85:384-88
78. Chang A, Kim K, Glick J, et al. 1993. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer; the Eastern Cooperative Oncology Group (ECOG) results. J. Natl. Cancer Inst. 85:388-94
79. Ceny T, Kaplan S, Pavlidis N, et al. 1994. Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br. J. Cancer 70:384-87
80. Francis PA, Rigas JR, Kris MG, et al. 1994. Phase II docetaxel in patients with stage III and IV non-small cell lung cancer. J. Clin. Oncol. 12:1232-37
81. Fossella FV, Lee JS, Murphy WK, et al. 1994. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J. Clin. Oncol. 12:1238-44
82. Burris H, Eckardt J, Fields S, et al. 1993. Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12:335 (Abstr.)
83. Fossella FV, Less JS, Shin DM, et al. 1995. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J. Clin. Oncol. 13:645-51
84. 2 with prednisone premedication in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13:364 (Abstr.)
85. Kunitoh H, Watanabe K, Onoshi T, et al. 1996. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer. J Clin. Oncol. 14:1649-55
86. Ettinger DS, Finkelstein DM, Sarma R, Johnson DH. 1993. Phase II study of taxol in patients with extensive-stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12:329 (Abstr.)
87. Kirschling RJ, Jung SH, Jett JR. 1994. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13:326 (Abstr.)
88. Smyth JF, Smith IE, Sessa C, et al. 1994. Activity of docetaxel (Taxotere) in small-cell lung cancer. Eur. J. Cancer 30A: 1058-60
89. Gelmon KA, Murray N, Melosky B, et al. 1996. Phase I/II study of biweekly paclitaxel (Taxol) and cisplatin in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 15:405
90. Belli L, Le Chavalier T, Gottfried M, et al. 1995. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 14:350 (Abstr.)
91. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. 1995. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 14:357 (Abstr.)
92. Zalcberg JR, Bishop JF, Millward MJ, et al. 1995. Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 14:351 (Abstr.)
93. Bonomi P, Kim K, Chang D, Johnson D. 1996. Phase III trial comparing etoposide, cisplatin, versus taxol with cisplatin-G-CSF versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc. Am. Soc. Clin. Oncol. 15:382 (Abstr.)
94. Langer CJ, Leighton JC, Comis RL, et al. 1995. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J. Clin. Oncol 13:1860-70
95. Choi H, Akerley W, Safran H, et al. 1994. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J. Clin. Oncol 12:2682-86
96. Forastiere AA, Neuberg D, Taylor SG, et al. 1993. Phase II evaluation of taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group Trial. Monogr. Natl. Cancer Int. 15:181-84
97. Au E, Ang PT, Chua EJ. 1996. Paclitaxel in metastatic nasopharyngeal cancer. Proc. Am. Soc. Clin. Oncol. 15:332 (Abstr.)
98. Catimel G, Verweij J, Mattijssen V, et al. 1994. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 5:533-37
99. Dreyfuss A, Clark J, Norris CN, et al. 1996. Docetaxel (Taxotere): an active drug against squamous cell carcinoma of the head and neck. J. Clin. Oncol. 14:1672-78
100. Bedikian AY, Weiss GR, Legha SS, et al. 1995. Phase II trial of docetaxel in patients with advanced cutaneous melanoma previously untreated with chemotherapy. J. Clin. Oncol. 13:1895-99
101. Aamdal S, Wolff I, Kaplan S. et al. 1994. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer 30A: 1061-64
102. Glantz MJ, Choy H, Kearns CM, et al. 1996. Phase I study of weekly outpatient paditaxel and concurrent cranial irradiation in adults with astrocytomas. J. Clin. Oncol. 14:600-9
103. Abbruzzese JL, Evans D, Gravel D, et al. 1995. Docetaxel, a potentially active agent for patients with pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 14:221 (Abstr.)
104. Ducreux M, Adenis A, Blanc C, et al. 1994. Phase II study of docetaxel in pancreatic adenocarcinoma. Ann. Oncol. 5(Suppl. 8): 406 (Abstr.)
105. Sulkes A, Smyth J, Sessa C, et al. 1994. Docetaxel in advanced gastric cancer: results of a phase II clinical trial. Br. J. Cancer 70:380-84
106. Einzig A, Lipsitz S, Wiernik PH, Benson AB. 1995. Phase II trial of Taxotere in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy. The Eastern Cooperative Oncology Group (ECOG) resuits. Proc. Am. Soc. Clin. Oncol. 14:191 (Abstr.)
107. Hudes GR, Obasaju C, Chapman A, et al. 1995. Phase I study of estramustine: preliminary activity in hormone-refractory prostate cancer. Sem. Oncol. 22(Suppl. 6): 6-11
108. McGuire WP, Blessing JA, Moore D, et al. 1996. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 14: 792-95
109. 2 intravenously over 1H every 21 days: a preliminary report. Proc. Am. Soc. Clin. Oncol. 15:293 (Abstr.)
110. Wilson HW, Chabner BA, Bryant G, et al. 1995. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 13:381-86
111. Younes A, Sarris A, Melnyk A, et al. 1995. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 13:583-87
112. Roth BJ, Dreicer R, Einhorn LH, et al. 1994. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urotheliurn: a phase II study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12:2264-70
113. Ajani JA, Ilson D, Daugherty L, et al. 1994. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst. 86:1086-91
114. Motzer R, Bajorin D, Schwartz L. 1994. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. Clin. Oncol. 12:2277-83
115. De Wit R, Stoter G, Blanc C, et al. 1994. Phase II study of first-line docetaxel (Taxotere) in patients with metastatic urothelial cancer. Ann. Oncol. 5(Suppl. 8): 67 (Abstr.)
116. van Hoesel QGCM, Verweij J, Catimel G. 1994. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcoma of the adult. Ann. Oncol. 5:539-42
117. Gill PS, Tulpule A, Reynolds T, et al. 1996. Paclitaxel (Taxol) in the treatment of relapsed or refractory AIDs-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol. 15: 306 (Abstr.)